516 related articles for article (PubMed ID: 31047972)
21. A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress.
Yegutkin GG; Salminen T; Koskinen K; Kurtis C; McPherson MJ; Jalkanen S; Salmi M
Eur J Immunol; 2004 Aug; 34(8):2276-85. PubMed ID: 15259025
[TBL] [Abstract][Full Text] [Related]
22. The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFalpha.
García-Vicente S; Abella A; Viguerie N; Ros-Baró A; Camps M; Testar X; Palacín M; Zorzano A; Marti L
J Physiol Biochem; 2005 Jun; 61(2):395-401. PubMed ID: 16180338
[TBL] [Abstract][Full Text] [Related]
23. Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats.
Somfai GM; Knippel B; Ruzicska E; Stadler K; Tóth M; Salacz G; Magyar K; Somogyi A
Neurochem Int; 2006 Jun; 48(8):746-52. PubMed ID: 16524643
[TBL] [Abstract][Full Text] [Related]
24. SSAO/VAP-1 protein expression during mouse embryonic development.
Valente T; Solé M; Unzeta M
Dev Dyn; 2008 Sep; 237(9):2585-93. PubMed ID: 18729210
[TBL] [Abstract][Full Text] [Related]
25. Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease.
Unzeta M; Solé M; Boada M; Hernández M
J Neural Transm (Vienna); 2007; 114(6):857-62. PubMed ID: 17393059
[TBL] [Abstract][Full Text] [Related]
26. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.
Bell RD; Zlokovic BV
Acta Neuropathol; 2009 Jul; 118(1):103-13. PubMed ID: 19319544
[TBL] [Abstract][Full Text] [Related]
27. Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition.
Carpéné C; Bizou M; Tréguer K; Hasnaoui M; Grès S
J Physiol Biochem; 2015 Sep; 71(3):487-96. PubMed ID: 25572340
[TBL] [Abstract][Full Text] [Related]
28. Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease.
Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Sarkar S
Neuroscience; 2020 Aug; 440():48-55. PubMed ID: 32450297
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer's amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood-brain barrier integrity, and angiogenesis.
Parodi-Rullán R; Ghiso J; Cabrera E; Rostagno A; Fossati S
Aging Cell; 2020 Nov; 19(11):e13258. PubMed ID: 33155752
[TBL] [Abstract][Full Text] [Related]
30. TNF-α and IL-1β Modulate Blood-Brain Barrier Permeability and Decrease Amyloid-β Peptide Efflux in a Human Blood-Brain Barrier Model.
Versele R; Sevin E; Gosselet F; Fenart L; Candela P
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142143
[TBL] [Abstract][Full Text] [Related]
31. Semicarbazide-Sensitive Amine Oxidase (SSAO) and Lysyl Oxidase (LOX) Association in Rat Aortic Vascular Smooth Muscle Cells.
Manasieva V; Thakur S; Lione LA; Patel J; Baydoun A; Skamarauskas J
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358914
[TBL] [Abstract][Full Text] [Related]
32. Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity.
Jargaud V; Bour S; Tercé F; Collet X; Valet P; Bouloumié A; Guillemot JC; Mauriège P; Jalkanen S; Stolen C; Salmi M; Smith DJ; Carpéné C
J Physiol Biochem; 2021 Feb; 77(1):141-154. PubMed ID: 32712883
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Semicarbazide-sensitive Amine Oxidase Reduces Atherosclerosis in Cholesterol-fed New Zealand White Rabbits.
Wang SH; Yu TY; Hung CS; Yang CY; Lin MS; Su CY; Chen YL; Kao HL; Chuang LM; Tsai FC; Li HY
Sci Rep; 2018 Jun; 8(1):9249. PubMed ID: 29915377
[TBL] [Abstract][Full Text] [Related]
34. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging.
del Mar Hernandez M; Esteban M; Szabo P; Boada M; Unzeta M
Neurosci Lett; 2005 Aug 12-19; 384(1-2):183-7. PubMed ID: 15894424
[TBL] [Abstract][Full Text] [Related]
35. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke.
Hernandez-Guillamon M; Solé M; Delgado P; García-Bonilla L; Giralt D; Boada C; Penalba A; García S; Flores A; Ribó M; Alvarez-Sabin J; Ortega-Aznar A; Unzeta M; Montaner J
Cerebrovasc Dis; 2012; 33(1):55-63. PubMed ID: 22133888
[TBL] [Abstract][Full Text] [Related]
36. Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer's Disease.
Parodi-Rullán R; Sone JY; Fossati S
J Alzheimers Dis; 2019; 72(4):1019-1039. PubMed ID: 31306129
[TBL] [Abstract][Full Text] [Related]
37. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
Kurz C; Walker L; Rauchmann BS; Perneczky R
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
[TBL] [Abstract][Full Text] [Related]
38. Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration.
Schilter HC; Collison A; Russo RC; Foot JS; Yow TT; Vieira AT; Tavares LD; Mattes J; Teixeira MM; Jarolimek W
Respir Res; 2015 Mar; 16(1):42. PubMed ID: 25889951
[TBL] [Abstract][Full Text] [Related]
39. Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains.
Soto-Rojas LO; Campa-Córdoba BB; Harrington CR; Salas-Casas A; Hernandes-Alejandro M; Villanueva-Fierro I; Bravo-Muñoz M; Garcés-Ramírez L; De La Cruz-López F; Ontiveros-Torres MÁ; Gevorkian G; Pacheco-Herrero M; Luna-Muñoz J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33915754
[TBL] [Abstract][Full Text] [Related]
40. HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.
Festoff BW; Sajja RK; van Dreden P; Cucullo L
J Neuroinflammation; 2016 Aug; 13(1):194. PubMed ID: 27553758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
